| Potency assay for therapeutic potential of coding nucleic acid |
2023-9-26 |
2023-10-12 |
|
| Coronavirus vaccine |
2023-6-26 |
2023-8-09 |
|
| Rna for treatment of autoimmune diseases |
2023-6-12 |
2023-10-19 |
|
| Method for reducing immunogenicity of rna |
2023-5-22 |
2023-6-15 |
|
| Binding agents binding to pd-l1 and cd137 and use thereof |
2023-5-11 |
2023-7-19 |
|
| Replicon compositions and methods of using same for the treatment of diseases |
2023-5-02 |
2023-11-09 |
|
| Nucleic acid compositions comprising a multivalent anion, such as an inorganic … |
2023-4-05 |
2023-10-12 |
|
| Agonistic tnf receptor binding agent |
2023-4-04 |
2023-6-20 |
|
| Formulation for administration of rna |
2023-3-30 |
2023-6-13 |
|
| Compositions |
2023-3-27 |
2023-5-10 |
|
| Individualized vaccines for cancer |
2023-3-22 |
2023-6-15 |
|
| Binding agents binding to epcam and cd137 |
2023-3-15 |
2023-9-21 |
|
| RNA LIPID NANOPARTICLES (LNPs) COMPRISING A POLYOXAZOLINE AND/OR POLYOXAZINE … |
2023-3-01 |
2023-9-07 |
|
| Preparation and storage of liposomal RNA formulations suitable for therapy |
2023-2-28 |
2023-4-06 |
|
| Tumor Antigens for Determining Cancer Therapy |
2023-2-28 |
2023-11-09 |
|
| Novel therapeutic uses of gardnerella endolysins |
2023-2-10 |
2023-8-17 |
|
| Agents and methods for targeted delivery to cells |
2023-2-02 |
2023-8-10 |
|
| Agents and methods for targeted delivery of nucleic acids to cells |
2023-2-02 |
2023-8-10 |
|
| Cyclic epitope tags |
2023-2-02 |
2023-8-10 |
|
| therapeutic rna for hpv positive cancer |
2023-1-31 |
2023-2-06 |
|
| Coronavirus vaccine |
2023-1-27 |
2023-9-28 |
|
| Pharmaceutical compositions for delivery of herpes simplex virus antigens and … |
2023-1-27 |
2023-8-03 |
|
| Analysis of rna molecules using catalytic nucleic acids |
2023-1-19 |
2023-7-27 |
|
| Lipid-based formulations for administration of rna |
2022-12-27 |
2023-7-06 |
|
| Modular drug production system |
2022-12-21 |
2023-6-29 |
|
| Engineered cell for inducing tolerance |
2022-12-20 |
2023-3-22 |
|
| Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing … |
2022-12-08 |
2023-6-15 |
|
| Methods and compositions for stimulating immune response |
2022-12-02 |
2023-3-14 |
|
| Agents for treatment of claudin expressing cancer diseases |
2022-12-02 |
2023-2-14 |
|
| Rna formulation for immunotherapy |
2022-11-30 |
2023-7-20 |
|
| Coronavirus vaccine |
2022-11-29 |
2023-10-26 |
|
| Coronavirus vaccine |
2022-11-29 |
2023-6-01 |
|
| Antibodies capable of binding to cd27, variants thereof and uses thereof |
2022-11-14 |
2023-7-06 |
|
| Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial … |
2022-11-09 |
2023-5-19 |
|
| Tlr7 agonist and combinations for cancer treatment |
2022-11-09 |
2023-5-19 |
|
| Selecting neoepitopes as disease-specific targets for therapy with enhanced … |
2022-11-02 |
2023-1-19 |
|
| Rna constructs and uses thereof |
2022-10-28 |
2023-11-02 |
|
| Dose determination for immunotherapeutic agents |
2022-10-27 |
2023-1-31 |
|
| Modification of rna, producing an increased transcript stability and … |
2022-10-25 |
2023-6-22 |
|
| Disulfide oligosaccharide compounds and complexes |
2022-10-21 |
2023-4-27 |
|
| Oligosaccharide complexes and uses |
2022-10-21 |
2023-4-27 |
|
| Oligosaccharide compounds and complexes |
2022-10-21 |
2023-4-27 |
|
| Compositions for administration of different doses of rna |
2022-10-21 |
2023-9-06 |
|
| Oligosaccharide compounds and complexes |
2022-10-21 |
2023-4-27 |
|
| Oligosaccharide complexes and uses |
2022-10-21 |
2023-4-27 |
|
| Modified replicable rna and related compositions and their use |
2022-10-17 |
2023-4-27 |
|
| Methods for determining mutations for increasing modified replicable rna … |
2022-10-17 |
2023-4-27 |
|
| Pharmaceutical compositions for delivery of viral antigens and related methods |
2022-10-14 |
2023-4-20 |
|
| Individualized vaccines for cancer |
2022-10-12 |
2023-6-22 |
|
| Therapeutic rna for lung cancer |
2022-10-10 |
2023-4-20 |
|
| Therapeutic rna for lung cancer |
2022-10-10 |
2023-4-20 |
|
| Multispecific binding agents against pd-l1 and cd137 in combination |
2022-10-05 |
2023-4-13 |
|
| Multispecific binding agents against pd-l1 and cd137 in combination with anti … |
2022-10-05 |
2023-4-13 |
|
| Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis … |
2022-9-29 |
2023-4-06 |
|
| 3'-utr sequences for stabilization of rna |
2022-9-28 |
2023-8-31 |
|
| Coronavirus vaccines and methods of use |
2022-9-22 |
2023-3-30 |
|
| Lipid-based rna formulations suitable for therapy |
2022-9-09 |
2023-3-16 |
|
| Formulation for administration of rna |
2022-9-07 |
2022-11-22 |
|
| Multispecific antibodies against CD40 and CD137 |
2022-9-06 |
2022-12-13 |
|
| Methods for diagnosing and treating cancer involving cancer stem cells |
2022-9-01 |
2023-1-19 |
|
| In vitro transcription technologies |
2022-8-23 |
2023-6-15 |
|
| Predicting T cell epitopes useful for vaccination |
2022-8-10 |
2022-9-01 |
|
| Antibodies for use in therapy. |
2022-8-03 |
2023-2-10 |
|
| Rna replicon for versatile and efficient gene expression |
2022-8-02 |
2022-11-09 |
|
| Compositions and methods for treatment of melanoma |
2022-7-28 |
2023-6-01 |
|
| Methods for predicting the usefulness of proteins or protein fragments for … |
2022-7-27 |
2022-8-25 |
|
| Methods and means for inducing an immune response |
2022-7-18 |
2022-11-03 |
|
| Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive … |
2022-7-13 |
2023-1-19 |
|
| Multispecific binding agents against cd40 and cd137 in combination therapy for … |
2022-7-13 |
2023-1-19 |
|
| Methods of inducing neoepitope-specific t cells with a pd-1 axis binding … |
2022-6-30 |
2022-12-01 |
|
| Combination dosage regime of cd137 and pd-l1 binding agents |
2022-6-20 |
2022-12-29 |
|
| prame tcr receivers |
2022-6-15 |
2023-6-20 |
|
| Device and method for accelerated thawing |
2022-5-25 |
2023-11-16 |
|
| Device and method for accelerated thawing |
2022-5-25 |
2022-12-01 |
|
| Technologies for early detection of variants of interest |
2022-5-04 |
2023-11-16 |
|
| Immunogen selection |
2022-5-04 |
2022-11-10 |
|
| Immunogen selection |
2022-5-04 |
2023-11-16 |
|
| Replicon compositions and methods of using same for the treatment of diseases |
2022-5-02 |
2023-11-09 |
|
| Lipid Particle Formulations for Delivery of RNA and Water-Soluble … |
2022-4-25 |
2022-8-11 |
|
| Virus vaccine |
2022-4-20 |
2023-11-02 |
|
| Virus vaccine |
2022-4-20 |
2023-11-16 |
|
| Virus vaccine |
2022-4-20 |
2022-10-27 |
|
| Rna compositions comprising a buffer substance and methods for preparing, … |
2022-4-11 |
2022-10-20 |
|
| Combination therapy with an anti-ca19-9 antibody and folfirinox in the … |
2022-3-24 |
2023-10-19 |
|
| Coronavirus vaccine |
2022-3-18 |
2023-3-09 |
|
| Multispecific binding agents against cd40 and cd137 in therapy |
2022-3-09 |
2022-9-15 |
|
| Recombinant vaccines and use thereof |
2022-3-07 |
2022-8-18 |
|
| Stable formulations of lipids and liposomes |
2022-3-02 |
2023-5-01 |
|
| Substituted imidazoquinolines as agonists of tlr7 |
2022-2-10 |
2022-8-04 |
|
| Predicting immunogenicity of T cell epitopes |
2022-2-10 |
2022-3-03 |
|
| Substituted imidazoquinolines |
2022-2-01 |
2022-7-21 |
|
| Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for … |
2022-1-30 |
2022-3-01 |
|
| Method for providing single-stranded RNA |
2021-12-23 |
2023-8-29 |
2023-8-29 |
| il2 agonists |
2021-12-22 |
2022-1-17 |
|
| TREATMENT SCHEDULE FOR PROTEINS CYTOKINES |
2021-12-20 |
2023-3-29 |
|
| Therapeutic rna for treating cancer |
2021-12-20 |
2023-10-25 |
|
| Therapeutic RNA for cancer treatment |
2021-12-20 |
2023-9-21 |
|
| RNA MANUFACTURE |
2021-12-07 |
2023-3-01 |
|
| RNA manufacturing |
2021-12-07 |
2023-9-08 |
|
| Antibody and taxane combination therapy |
2021-12-07 |
2023-6-22 |
|